Morgan Stanley
AH

Morgan Stanley’s Accretive Health AH Stock Holding History

Morgan Stanley’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-117,049
Closed -$936K – 6831
2014
Q1 		$936K Buy
117,049
+92,209
+371% +$817K ﹤0.01% 4041
2013
Q4 		$227K Sell
24,840
-29,125
-54% -$251K ﹤0.01% 4966
2013
Q3 		$493K Buy
+53,965
New +$536K ﹤0.01% 4348

Other funds holding AH

JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RMC
Regis Management Company Menlo Park, California $331M AUM 14.13% 1-Year Est. Return
BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
ECM
EII Capital Management New York $774K AUM 22.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
MIM
Merion Investment Management Bay Harbor Islands, Florida $1.26M AUM 28.57% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
SCM
Stonebridge Capital Management Los Angeles, California $208M AUM

Morgan Stanley's AH Position: Q2 2014 in Review

Morgan Stanley sold out of Accretive Health (AH) in Q2 2014, closing a stake of 117,049 shares — an estimated $936K sold.

Morgan Stanley first reported a position in AH in Q3 2013 and held it in 3 quarters. The position peaked at $936K in Q1 2014. 12 funds tracked by Wall St. Rank hold AH as of Q2 2014.

  • Morgan Stanley reported no remaining Accretive Health position as of Q2 2014 after selling out during the quarter.
  • Morgan Stanley sold 117,049 Accretive Health shares in Q2 2014, an estimated $936K.
  • Morgan Stanley first reported a position in Accretive Health in Q3 2013 and held it in 3 quarters.
  • Morgan Stanley's Accretive Health position peaked at $936K in Q1 2014.
  • 12 funds tracked by Wall St. Rank held Accretive Health as of Q2 2014.

Based on Morgan Stanley's 13F filing for Q2 2014, filed 12 Aug 2014.